Shushan Hovsepyan, Pediatric Oncologist and Research Coordinator at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“What is the optimal way of effective drug development for ultra-rare cancers? Let’s take an example from Alveolar Soft Part Sarcomas (ASPS). Only 60 new cases are diagnosed a year in Europe, and there have been just two major studies ever conducted.

But there’s hope. By working together, researchers, patient groups, industry, and those who approve new drugs can make it easier to find and approve new treatments for rare cancers like ASPS. Learn more in the latest article published in the Journal of Clinical Oncology.”

Source: Shushan Hovsepyan/LinkedIn